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ABSTRACT 
Anti-PL-7 is an anti-tRNA synthetase antibody (ARS) and interstitial lung disease (ILD) is 
the most frequent complication of anti-PL-7-associated antisynthetase syndrome (ASS). 
However, the features of ILD have not been fully elucidated. The present study 
retrospectively compares seven and 15 patients who were positive for anti-PL-7 and anti-Jo-1 
antibodies, respectively. The features of ILD did not significantly differ between the two 
groups, but the ratio of lymphocytes in bronchoalveolar lavage fluid was higher in the Jo-1, 
than in the PL-7 group. High-resolution computed tomography revealed nonspecific 
interstitial pneumonia in all patients in the PL-7 group and organizing pneumonia in four of 
the 15 patients in the Jo-1 group. These findings suggest that pulmonary complications 
slightly differ between patients expressing anti-PL-7 and anti-Jo-1 antibodies. Further studies 
are required to clarify the features of ILD associated with PL-7. 
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Introduction 
Antisynthetase syndrome (ASS) is characterized as inflammatory myositis, fever, arthritis, 
Raynaud's phenomenon, mechanic's hands, and interstitial lung disease (ILD) associated with 
the expression of anti-tRNA synthetase antibodies (ARS) [1]. Anti-Jo-1 (anti-histidyl) 
antibody is the most common, but other anti-ARS including anti-PL-12, anti-PL-7, anti-OJ, 
and anti-EJ tRNA-synthetase antibodies are now routinely diagnosed in Europe using 
immunoblot assays [2]. Thus, the features of each ASS have become clearer [3, 4]. Interstitial 
lung disease associated with ARS is the most prevalent ASS manifestation and it is the main 
cause of morbidity and mortality in ASS [1, 3],[5]. Anti-PL-7 antibody is directed against 
threonyl-tRNA synthetase, and it accounts for 10% - 15% of all ARS cases [6]. Interstitial 
lung disease is the most frequent complication of anti-PL-7-related ASS, occurring in 80% of 
patients [6], but the features have not been fully elucidated. On the other hand, ILD in 
patients with anti-Jo-1 antibody has been described in detail [7-9]. Here, we aimed to clarify 
the features of ILD by comparing patients expressing anti-PL-7 and anti-Jo-1 antibodies. 
 
Materials and methods 
Study population 
The medical records of seven consecutive patients expressing anti-PL-7 and 14 expressing 
anti-Jo-1 who were admitted to Nagasaki University Hospital between November 2001 and 
March 2013 were retrospectively analyzed. Polymyositis and dermatomyositis (PM/DM) 
were diagnosed based on the Bohan and Peter criteria [10], and DM was distinguished from 
PM by the presence of a heliotrope rash or Gottron’s lesions. The diagnosis of CADM was 
based on the criteria proposed by Sontheimer [11], namely clinical skin manifestations typical 
of DM but minimal or absent clinical features of myositis for >2 years after the onset of skin 
manifestations. Serum anti-PL-7 antibody was measured using RNA immunoprecipitation 
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assays [3] (n = 6) or a Myositis Profile 3 EuroLine immunoblot assay (Euroimmun, Lübeck, 
Germany) (n = 1). Serum anti-Jo-1 antibody was determined using an enzyme-linked 
immunosorbent assay (SRL Inc., Tokyo, Japan). 
 
Evaluation of ILD 
All patients were assessed by chest radiography and high-resolution computed tomography 
(HRCT). Two independent observers who were unaware of the patients’ profiles categorized 
the HRCT findings as organizing pneumonia (OP) with peribronchial or subpleural 
consolidation or ground-glass opacities without fibrosis, or as nonspecific interstitial 
pneumonia (NSIP) characterized by patchy or diffuse ground-glass opacities with associated 
reticular opacities, traction bronchiectasis, and bronchiolectasis. Divergent conclusions were 
resolved by consensus between the two observers. Pulmonary function results were 
considered abnormal when the ratio (%) of vital capacity (%VC) and the ratio (%) of 
diffusing capacity for carbon monoxide (%DLCO) were < 80%. Bronchoalveolar lavage 
(BAL) fluid was collected with three instillations of sterile physiological saline (50 mL) 
through a flexible bronchoscope as described [12]. Differential cell counts in BAL were 
evaluated according to the American Thoracic Society Guidelines; lymphocytes > 15%, 
neutrophils > 3%, and eosinophils > 1% were considered excessive [13]. Responses to ILD 
therapy were evaluated according to the criteria for idiopathic pulmonary fibrosis [14]. The 
Human Ethics Review Committee of Nagasaki University School of Medicine approved the 
study protocol.  
 
Statistical analysis 
All values are expressed as means ± SD unless otherwise stated. Differences between groups 
were compared using an unpaired t-test for means and Fisher's exact test for counts. Values 
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with P < 0.05 were regarded as significantly different. 
 
Results 
Clinical features of patients with anti-PL-7 antibody   
Table 1 shows the clinical features at the time of the first presentation determined from the 
seven female patients (age, 47 ± 14 years) expressing anti-PL-7 antibody. All clinical data 
including CT findings were obtained before treatment with prednisolone and 
immunosuppressants. Muscle involvement, Raynaud’s phenomenon, and mechanic’s hand 
were evident in 3, 3 and 2 of them, respectively. Laboratory findings showed elevated levels 
of creatine kinase (CK) and of Krebs von den Lungen (KL-6) protein in four and in all seven 
patients, respectively. Chest HRCT revealed NSIP in all patients. A surgical lung biopsy from 
one patient confirmed NSIP. Pulmonary function tests showed restrictive (5/7 patients) and 
diffusive (5/6 patients) types, but not obstructive impairment (data not shown). Ratios of 
lymphocytes, neutrophils, and eosinophils were elevated in BAL fluid from 5, 6 and 7 
patients, respectively, and CD4/CD8 ratios were lower in five of the seven patients. Five 
patients were treated with prednisolone and an immunosuppressant, one received 
prednisolone alone, and one was not treated. The clinical course of ILD improved, stabilized, 
and deteriorated in 2, 2 and 3 patients, respectively. 
 
Comparison of features between patients expressing anti-Jo-1 and anti-PL-7 antibodies  
We compared the characteristics including pulmonary involvement between patients 
expressing anti-Jo-1 and anti-PL-7 antibodies. Table 2 shows the clinical characteristics at 
initial presentation. Sex, age, and smoking history, as well as pulmonary, muscle and skin 
findings did not significantly differ between the two groups. Raynaud’s phenomenon was 
statistically more prevalent in the PL-7 group, whereas other symptoms including dyspnea, 
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cough and fever were not. The frequency of clinical diagnoses including DM, PM, CADM, 
and ILD without skin and muscle symptoms did not differ. One and two patients in the PL-7 
Jo-1 groups, respectively, also had Sjögren’s syndrome. Preceding pulmonary or skin/muscle 
symptoms also did not differ. Table 3 shows the clinical parameters at initial presentation. 
Markers of ILD including serum KL-6, surfactant protein (SP)-D, SP-A, and LDH, as well as 
levels of the muscle enzymes CK and aldolase did not differ between the groups. Arterial 
blood gas analysis in room air revealed significant decreased levels of PaO2 in the Jo-1, 
compared with the PL-7 group. The results of pulmonary function tests (%VC, FEV1/FVC%, 
and %DLCO) did not differ between the groups. The ratio of lymphocytes was significantly 
elevated in BAL fluid from the Jo-1 group. The proportions of patients with > 15% 
lymphocytes, > 5% neutrophils and > 1% eosinophils in BAL fluid did not differ between the 
groups. The HRCT findings such as ground grass opacity and reticular shadows were 
common to both groups at a lower and peripheral predominance. All patients in the PL-7 
group had signs of NSIP, whereas four patients in the Jo-1 group had signs of OP. Traction 
bronchiectasis was more prevalent in the PL-7, than in the Jo-1 group (100% vs. 64.3%), but 
the difference did not reach significance. Other findings were essentially the same between 
the two groups. The only clinical parameter that differed between the NSIP and OP findings 
in the Jo-1 group was a lower PaO2 in OP (data not shown). The clinical course of pulmonary 
involvement was also evaluated. The median follow-up was longer for patients with PL-7 
than with Jo-1 (68 vs. 30 months), but the difference did not reach significance. Most patients 
in both groups were treated with prednisolone and immunosuppressants. One patient in the 
PL-7 group received only long-term oxygen therapy. None of the patients died during the 
follow-up period. The clinical course of pulmonary involvement, as well as %VC 
and %DLCO did not differ between the groups, although only half of the Jo-1 group could be 
evaluated (data not shown). 
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Discussion 
We compared patients expressing anti-PL-7 and anti-Jo-1 antibodies to elucidate the features 
of ILD in patients expressing anti-PL-7 antibody, which was associated with several features 
of ILD. 
Chest CT findings of all patients expressing anti-PL-7 showed signs of NSIP. Previous 
studies of ILD associated with anti-PL-7-related ASS have described pulmonary HRCT 
findings as NSIP, OP and usual interstitial pneumonia (UIP), with the most prevalent findings 
being NSIP [4]. Pulmonary HRCT findings of patients with anti-PL-7 predominantly showed 
NSIP (43-75%) [6],[15]. The finding of UIP in pulmonary HRCT of patients expressing 
anti-Jo-1 is reportedly associated with ILD deterioration, whereas the OP finding in such 
patients is not [9]. Further studies are needed to determine whether or not chest CT findings 
can predict the prognosis of patients expressing anti-PL-7. 
The differential cell findings in BAL fluid revealed a higher proportion of lymphocytes in the 
Jo-1 group. A study of 12 patients expressing anti-PL-7 found increased numbers of 
neutrophils (n = 5) or lymphocytes (n = 3) in BAL fluid from eight patients, indicating 
alveolitis [15]. One study found an elevated ratio of neutrophils in BAL fluid from a group of 
patients with progressive PM/DM, while that of lymphocytes remained normal [16]. 
A previous study found a poorer outcome of ILD for patients expressing anti-PL-7 and PL-12 
compared with anti-Jo-1 [17]. Furthermore, five-year survival rates were lower for those 
expressing anti-PL-7 than anti Jo-1 (67% vs. 90%) and pulmonary causes of death 
(pulmonary fibrosis and pulmonary hypertension) were common in patients expressing 
anti-Jo-1 (19/36; 53%) and anti-PL-7 (11/14; 79%) [18]. The HRCT findings of NSIP and 
neutrophilic inflammation in the lungs might be related to poorer survival for patients 
expressing anti-PL-7 compared with anti-Jo-1. 
The present study is limited by the small patient cohort and by potential selection bias 
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resulting from measuring anti-Jo-1 Ab and anti-PL-7 Ab. Anti-Jo-1 Ab is routinely and 
measured commercially when CVD-IP is suspected in the Japanese clinical setting. Thus, 
anti-Jo-1 Ab our institution is routinely measured in patients who present at our institution 
with interstitial pneumonias that mimic interstitial lung disease associated with antisynthetase 
syndrome. On the other hand, anti-PL-7 Ab is measured in university, not commercial 
laboratories, when antisynthetase syndrome and anti-Jo-1 Ab negative status is suspected. 
  
The present study found a slight difference in pulmonary complications between patients 
expressing anti-PL-7 and anti-Jo-1 antibodies. Further studies are required to define the 
features of pulmonary complications in patients expressing anti-PL-7 antibodies. 
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Table 1. Characteristics of patients with anti-PL-7 antibody.
1 2 3 4 5 6 7
Sex (F/M) F F F F F F F
Age (y) 55 51 28 62 54 25 53
Muscle involvement + + - - - + -
Raynaud's phenomenon - - + + + - -
Mechanic's hand - + - - + - -
CK (IU/L) 1632 1409 154 1988 68 1025 77
KL-6 (U/mL) 1000 833 2155 1770 1460 1010 538
HRCT pattern NSIP NSIP NSIP NSIP NSIP NSIP NSIP
%VC 54.8 58.3 67.9 56.6 108.4 62.2 90.2
%DLCO 42.1 33.8 47.7 49.5 81.1 ND 71.6
BALF findings
 Lymphocytes (%) 21.1 40.7 20.8 55.1 33.0 12.1 14.6
 Neutrophils (%) 34.3 37.4 7.7 1.4 3.9 5.7 7.8
 Eosinophils (%) 9.0 11.8 7.1 1.9 1.4 3.8 8.9
 CD4/CD8 0.3 0.5 0.2 7.7 2.3 0.03 0.8
Therapy P, IM P, IM P, IM P, IM - P P,IM
Clinical course (I/S/D) S I D I D D S
 I, improvement; D, deterioration; IM, immunosuppressant; ND, no data.
 P, prednisolone; S, stable. 
Table 2. Comparison of clinical characteristics of patients with anti-PL-7 and anti-Jo-
                antibodies.
PL-7 (N = 7) Jo-1 (N = 14) p
Sex (M:F) 0:7  3:11 0.27
Age 47 ± 14 55 ± 12 0.23
Smoking history 0 (0%) 5 (35.7%) 0.10
Symptoms
Dyspnea 4 (57.1%) 2 (16.7%) 0.64
Cough 4 (57.1%) 13 (92.9%) 0.09
Fever 3 (42.9%) 2 (14.3%) 0.18
Raynaud's phenomenon 3 (42.9%) 0 (0%) 0.03
Physical findings
Fine crackle 6 (85.7%) 11 (78.6%) 0.59
Muscle weakness 2 (28.6%) 6 (42.9%) 0.44
Polyarthritis 2 (28.6%) 3 (21.4%) 0.56
Heliotrope 2 (28.6%) 1 (7.1%) 0.25
Gottron's papules 3 (42.9%) 3 (21.4%) 0.30
Mechanic’s hand 2 (28.6%) 3 (21.4%) 0.56
Clinical diagnosis (DM/PM/CADM/IP) 5/0/2/0 5/2/5/2 0.35
Other CTD SjS 2 SjS 1
Preceding symptoms
(Lung/skin・muscle/simultaneous)
 CADM, clinically amyopathic dermatomyositis;  CTD, connective tissue disease.
 DM, dermatomyositis; I, immunosuppressant; PM, polymyositis; PSL, prednisolone
3/2/2 7/6/1 0.41
Table 3. Comparison of clinical parameters between patients with anti-PL-7
                and anti-Jo-1 antibodies. 
PL-7 Jo-1 p 
Laboratory findings N = 7 N = 14
 KL-6 (U/mL) 1351 ± 664 675 ± 502 0.30
 SP-D (ng/mL) 238 ± 161 171 ± 27 0.99
 SP-A (ng/mL) 86.6 ± 37.2 56.7 ± 0.4 0.59
 LDH (IU/L) 286 ± 129 372 ± 97.6 0.82
 CK (IU/L) 739 ± 900 1082 ± 974 0.77
 Aldolase (IU) 16.4 ± 14.6 37.5 ± 13.4 0.66
 PaO2 (Torr) 87.7 ± 7.6 82.2 ± 10.6 0.02
Pulmonary function tests N=7 N=10
 %VC 76.3 ± 22.4 69.0 ± 24.4 0.27
 FEV1/FEV% (%) 86.1 ± 4.8 84.9 ± 5.5 0.19
 %DLCO 56.7 ± 19.2 45.1 ± 11.9 0.69
BALF cell findings N = 7 N = 13
 Total cells (x 105/mL) 2.6 ± 2.0 9.7 ± 0.8 0.18
 Macrophages (%) 49.1 ± 24.8 15.4 ± 13.6 0.18
 Lymphocytes (%) 32.8 ± 16.1 71.7 ± 4.7 0.04
 Neutrophils (%) 11.6 ± 14.7 6.6 ± 7.8 0.73
 Eosinophils (%) 6.2 ± 4.5 6.0 ± 0.7 0.66
 CD4/CD8 2.3 ± 3.1 0.2 ± 0.3 0.32
CT findings N = 7 N = 14
Ground glass opacity 6 (85.7%) 14 (100%) 0.33
Reticular shadow 7 (100%) 12 (85.7 %) 0.43
Consolidation 2 (28.6%) 8 (57.1 %) 0.22
Peribronchovascular thickening 0 (0%) 0 (0%) 1.00
Traction bronchiectasis 7 (100%) 9 (64.3%) 0.10
Honeycombing 0 (0%) 0 (0%) 1.00
Predominance  (upper/lower) 0/7 2/12 0.43
Predominance  (peripheral/central) 7/0 13/1 0.67
NSIP/OP 7/0 10/4 0.17
NSIP, nonspecific interstitial pneumonia; OP, organizing pneumonia.
